Exhibit 99.1
JOINT FILING AGREEMENT
In accordance withRule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the common stock, par value $0.0001 per share, of LogicBio Therapeutics, Inc,, a Delaware corporation, and further agree that this Joint Filing Agreement be included as an exhibit to such joint filings. In evidence thereof, each of the undersigned hereby executes this Joint Filing Agreement as of November 2, 2018.
| ARIX BIOSCIENCE PLC | ||
| By: | /s/ James Rawlingson | |
| Name: | James Rawlingson | |
| Title: | Chief Financial Officer | |
| ARIX BIOSCIENCE HOLDINGS LIMITED | ||
| By: | /s/ James Rawlingson | |
| Name: | James Rawlingson | |
| Title: | Director | |
/s/ Daniel P. O’Connell, M.D., Ph.D. | ||
| Daniel P. O’Connell, M.D., Ph.D. | ||
